EUVIMEDEUVIMED entdecken
EditorialKommentar

The pursuit of mechanistic links between sleep disturbances and pain: are we getting warmer?

Daniel Whibley, Tiffany J Braley iD

SLEEP · 2023

DOI: 10.1093/sleep/zsad092 ↗

Kurz gefasst

Editorial in der Zeitschrift SLEEP, 2023. Verfasst von Daniel Whibley und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Prostaglandin-Endoperoxide Synthases, Endocannabinoids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sleep disturbances are important potential drivers of pain onset, severity, and persistence [1]. Consequently, sleep health is being increasingly recognized as a foundational component of interventions to prevent or alleviate chronic pain. However, findings regarding biological mechanisms that could explain the effect of sleep disturbances on pain sensitization and/or inhibition remain scant, and carefully designed studies to elucidate neurobiological and immunologic underpinnings are sorely needed. The elegant study by Haack et al. in this issue of SLEEP provides early but promising evidence to fortify the tenability of previously proposed mechanistic pathways that link sleep and pain [2]. Sex-differential effects are also highlighted that, if replicated, hold pivotal clinical importance given the higher prevalence of chronic pain conditions consistently observed among women [3–5]. Candidate neurobiological mechanisms by which sleep disturbances could exert their effect on the pain experience have previously been reviewed by Haack et al., including endocannabinoid-, immune-, monoaminergic-, opioid-, orexinergic-, and melatonin-based pathways, adenosine and nitric oxide signaling, and the hypothalamic–pituitary–adrenal axis [6]. The current study focused on associations between an intelligently designed experimental sleep disturbance paradigm (versus a within-participant control condition) and three pathways postulated to lead to pain-related outcomes: central pain modulation, the cyclooxygenase (COX) pathway, and endocannabinoid pathways. The investigators then explored the possibility of sex-specific differences on pathway activation. Although the study was not powered for the evaluation of sex differences, this exploration is justified by prior supportive evidence for sex-specific associations between sleep disturbances and central nervous system descending pain inhibition, inflammatory responses, and components of the endocannabinoid system [7–12]. Although the experimental sleep disturbance condition (relative to the control condition) was not associated with sample-wide differences in centrally mediated pain inhibition, analysis of sex differences revealed divergence. After experimental sleep disturbance, pain inhibition responses were attenuated in females, and paradoxically increased in males, regardless of the testing paradigm (Conditioned Pain Modulation or Habituation to Repeated Pain). These findings align with previously demonstrated associations between total sleep deprivation and impaired descending pain inhibition in females [8]. Importantly, in the present study, recovery sleep (either intermittent or extended) was not associated with improved measures of pain inhibition in females, suggesting that sleep disturbances could exert both durable and deleterious effects on pain-related outcomes. Although the extent of this durability requires further exploration, these findings suggest that impairment of the descending inhibitory system may play an important and unique mechanistic role in the sleep-pain pathway in females. Haack et al. have previously investigated several putative inflammatory mediators of the sleep-pain pathway, including Prostaglandin E2 metabolite levels [13]. Using the dataset collected for the current study, they have also reported sex-specific differences in several inflammatory markers and immune cell profiles after experimental sleep disturbance [14]. Interestingly, in the latter study, females exhibited lower plasma levels of IL-6 and a reduced percentage of lipopolysaccharide-stimulated IL-6-positive monocytes, relative to males, following sleep disturbance. Building on these findings, the current study examined intracellular COX-2 expression by monocytes in stimulated and unstimulated conditions in the setting of sleep disturbances. Expression increased following the experimental sleep condition when compared to the non-disturbed sleep control condition, but—in parallel with findings contained in the earlier report from this dataset—only in males. In contrast to the finding of female-specific impairment in central pain inhibition, these collective findings suggest that males may exhibit more aberrant inflammatory responses to experimental sleep disturbance. Taken together, these research trends indicate that the identification of methods to amplify or block specific pathways between disturbed sleep and pain may require a sex-specific approach. Unlike the aforementioned neurobiological pathways examined, plasma levels of endocannabinoids were not associated with sex-specific differences. In addition to immunomodulatory properties, the endocannabinoid system exerts neuromodulatory effects, and is involved in the regulation of both sleep and pain [15–18]. Circulating levels following a diurnal rhythm, with a peak during wakefulness and a nadir prior to sleep onset [19]. In the current study, only docosahexaenoyl ethanolamide was shown to significantly change following experimental sleep disruption. Given the complexity of the endocannabinoid system, and differential expression and effects within and outside of the central nervous system, additional work is needed to illuminate its role in modulation of pain, including within the context of sleep disturbance and/or deprivation. A notable feature of the study by Haack et al. is the health status and demographic characteristics of the participants. None of the participants were living with chronic pain. Given the possibility of dysregulated central pain modulation, inflammatory, or endocannabinoid pathways that may invoke/be invoked by a chronic pain state, generalizability of this study’s findings to specific pain populations is limited. Further, restriction of the age inclusion criterion of 18–45 years and a body mass index inclusion criterion of 18.5–30 kg/m2 prevented exploration of the potential moderating effects of older age and obesity that should be examined in future studies. Indeed, older age and obesity are common risk factors for chronic pain. Notably, although this study was not designed (and therefore not powered) to reveal sex-specific effects, their detection provides some justification and support for the time and expense—and non-trivial participant burden given the involved experimental sleep disruption paradigm—required to replicate the findings with people living with chronic pain. Rich phenotyping of those with chronic pain, including presence and/or extent of different pain phenotypes (i.e., nociplastic, neuropathic, and/or peripheral pain), as well as quantification of effects on sensory and/or affective components of pain, could provide more information on links that may be not only sex- but also pain mechanism specific. Additionally, this study’s separate analyses of different pathways that demonstrated weakened pain inhibition yet anti-inflammatory effects of sleep disruption in females, and the opposite in males (augmented pain inhibition and pro-inflammatory effects), raise questions about the overall effect (and relative contributions) of multiple pathways in each sex. Irrespective of these areas for development, findings of sex-specific differences should be viewed as enticing at this stage, and highlight the need for large-scale, mechanistic work in representative populations to disentangle the complex pathways that connect sleep and chronic pain. DW has no financial conflicts of interest to declare. TJB has consulted for Bluestar BioAdvisors. DW has no non-financial conflicts of interest to declare. TJB’s research is supported by the NIH/NCCIH, NIH/NIA, and PCORI. She receives material support from Jazz Pharmaceuticals for an NCCIH-funded IIT but receives no financial support or compensation from Jazz for this work. She is site principal investigator for several industry-sponsored studies of MS immunotherapeutics at the University of Michigan but receives no compensation for this work. She is also named in a patent, held by the University of Michigan, concerning treatment for sleep apnea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostaglandin-Endoperoxide SynthasesEndocannabinoidsHumansPainSleep

Substanzen

Prostaglandin-Endoperoxide SynthasesEndocannabinoids

Autor:innen und Institutionen

  • Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA.
  • Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA.
  • Department of Neurology, Divisions of Neuroimmunology/Multiple Sclerosis and Sleep Medicine, University of Michigan Ann Arbor, Ann Arbor, MI, USA.

ORCID-Profile: Tiffany J Braley

Zitieren

APA

Whibley, D., & Braley, T. J. (2023). The pursuit of mechanistic links between sleep disturbances and pain: are we getting warmer?. SLEEP. https://doi.org/10.1093/sleep/zsad092

Vancouver

Whibley D, Braley TJ. The pursuit of mechanistic links between sleep disturbances and pain: are we getting warmer?. SLEEP. 2023. doi:10.1093/sleep/zsad092

BibTeX
@article{Whibley2023,
  author = {Whibley, Daniel and Braley, Tiffany J},
  title = {The pursuit of mechanistic links between sleep disturbances and pain: are we getting warmer?},
  journal = {SLEEP},
  year = {2023},
  doi = {10.1093/sleep/zsad092}
}
Kostenlos starten →